Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 4/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 10/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3473446 | 0.92 | TGFBR1 (0.44) | SCDGRIN1GRIN2BTGFBR1BRD9 | |
| SCHEMBL3350638 | 0.89 | PIN1 (0.45) | SCDGRIN1GRIN2B | |
| SCHEMBL3376765 | 0.85 | TRPC5 (0.46) | GRIN1GRIN2B | |
| SCHEMBL3476237 | 0.81 | PIN1 (0.43) | SCDGRIN1GRIN2BTGFBR1 | |
| SCHEMBL3473761 | 0.80 | S1PR1 (0.41) | SCD | |
| SCHEMBL3473451 | 0.79 | KMO (0.43) | SCDGRIN1GRIN2B | |
| SCHEMBL3474070 | 0.78 | TGFBR1 (0.49) | GRIN1GRIN2BTGFBR1BRD9 | |
| SCHEMBL3476567 | 0.78 | GRIN1 (0.41) | SCDGRIN1GRIN2BTGFBR1 | |
| SCHEMBL3475918 | 0.77 | GRIN2B (0.41) | GRIN1GRIN2B | |
| SCHEMBL3435475 | 0.77 | GRIN2B (0.41) | GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010053757-A1 | 2 -OXOQUINOXALIN BLOCKERS OF THE LATE SODIUM CHANNEL | GILEAD PALO ALTO, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| US-20100113461-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-8912190-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20100113461-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113461-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, KCNJ2, KCNH2 | SCD 2432/4885GRIN1 1435/4885GRIN2B 2067/4885 |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, KCNJ2, KCNH2 | SCD 2432/4885GRIN1 1435/4885GRIN2B 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.